We hope you are finding care and support during these trying times in our world. It is a time of grief and mourning as well as a call to awareness, change, and action. You can read more about how MAPS-sponsored MDMA-assisted psychotherapy trials are responding to COVID-19 and the MAPS Statement of Solidarity. The MDMA Therapy Training Program is carrying out an educational design project to further develop the training pedagogy and competency framework to support the growth and continued quality of the program over the coming years. This training design initiative includes the development of more extensive and effective training resources to support culturally-relevant and informed care in MDMA therapy protocols. Our program staff are currently engaged in expanding efforts to support therapists of color to receive training and resources to enter the practice of MDMA therapy. Our goal is for all people who could benefit from MDMA therapy to have access to compassionate and supportive treatment, including and especially communities of color that have been historically underserved.
Additionally at this time, the training program continues to support clinical supervision of active MDMA-assisted psychotherapy studies, as many study sessions are continuing with safety practices in place for COVID-19.
MAPS Trainers Annie Mithoefer, B.S.N., and Michael Mithoefer, M.D., are collaborating with the CIIS Certificate in Psychedelic-Assisted Therapies and Research program to deliver training in MDMA-assisted psychotherapy in a hybrid online and in-person format. The online training was delivered over two weekends in June with support from MDMA Therapy Training Program staff.